Evidence map›Paper›PMID 32839526›Full record

ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2020

Learning from lorcaserin: lessons from the negative clinical trial of lorcaserin to treat cocaine use disorder.

S Stevens Negus, Matthew L Banks

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03192995 (Treatment With Lorcaserin for Cocaine Use), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03192995 phase2terminatednot on this map

Treatment With Lorcaserin for Cocaine Use: The TLC Study

TypeinterventionalSponsorGlenn-Milo SantosRan2018 to 2020Enrolled22ConditionsCocaine Use DisorderArmslorcaserin, Placebo Oral Tablet, Substance use counseling, ACASI, Cocaine metabolites
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

S Stevens NegusDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, 23298, USA. sidney.negus@vcuhealth.org.
Matthew L BanksDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Virginia Commonwealth University · US

Funding

Immunopharmacotherapy for Mitigating Opioid AddictionUH3DA041146 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI JANDA, KIM · 2017 to 2019
$4.4M
Medications Development for Stimulant AbuseR01DA026946 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI NEGUS, SIDNEY S · 2009 to 2019
$3.7M
Treatment Development for Methamphetamine AbuseR01DA031718 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI BANKS, MATTHEW L · 2012 to 2014
$1.1M
NIDA NIH HHS R01 DA026946NIDA NIH HHS R01 DA031718NIDA NIH HHS UH3 DA041146
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BenzazepinesCocaineClinical Trials as TopicHumansSerotonin 5-HT2 Receptor AgonistsBenzazepinesCocainelorcaserinSerotonin 5-HT2 Receptor Agonists

Identifiers

PMID32839526
PMCPMC7547654
OpenAlexW3081218245

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.